Regen BioPharma, Inc. (OTC: RGBP) surged up 26.29% to $0.0032 at the Friday’s close. The volume of RGBP stock was 129.20M in contrast with its Average Weekly volume of 73.07M. RGBP stock took a leap after release of a year-end shareholder letter.
What RGBP has imparted to shareholders?
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Regen BioPharma is a public biotechnology organization zeroed in on the immunology and immunotherapy space. RGBP is centered around quickly propelling novel advances through pre-clinical and Phase I/II clinical preliminaries. At present, RGBP is centered around little atom treatments for treating malignant growth and immune system problems.
Regen BioPharma released a year-end letter from David R. Koos Chairman and CEO of RGBP, to the Company’s investors.
Shareholders’ letter in a glimpse:
- For RGBP, it has been a drawn out year with many difficulties and numerous victories.
- At his re-visitation of RGBP on March 23, 2021 in his present job, Koos ended up in charge of an organization nearly breakdown.
- RGBP was behind in bills, in danger of losing patent security on important IP, and delinquent in its SEC recording commitments.
- More regrettable of all RGBP was being sued by its Contract Research Organization Chemdiv in a grievance looking for harms of $1,200,000 which likewise compromised its proprietorship freedoms to important licensed innovation
- As the year advanced RGBP confronted the difficulties that lay before it and vanquished them.
- Becoming current in its SEC announcing commitments later such a long wrongdoing was a critical accomplishment. Late changes to SEC Rule 15c2-11 compromised the public exchanging status of delinquent guarantors.
- During the quarter finished June 30, 2021 RGBP was paid $1,905,000 in real money and protections coming about because of two licenses conceded in April, 2021 to Oncology Pharma, Inc. (“ONPH”).
- According to the agreements of the licenses allowed ONPH became committed to pay nonrefundable expenses of $55,000 and 50,000 normal portions of ONPH no later than April 20, 2021
- ONPH was additionally committed to pay sovereignties equivalent to five percent (5%) of the Net Sales (as Net Sales are characterized in the Agreement) of any Licensed Products in a quarter.
- An ensuing assessment related to the Company’s public bookkeeper drove RGBP to reevaluate this bookkeeping treatment still up in the air that – to be consistent with ASC 606-the income created by the installment to the Company of the nonrefundable charges should be perceived over the term of the licenses.
What RGBP has accomplished?
Regen BioPharma (RGBP) has restored various important existing IP which had been considered deserted by the United States Patent and Trademark Office, settled its claim with Chemdiv, been given a few new licenses, went into two non-related party authorizing arrangements. RGBP likewise became current in its SEC documenting commitments taking out the danger that the public exchanging market for both the common and Series A preferred shares would vanish.
